Bill Andrews, PhD President & CEO at Sierra Sciences Testimonial

Bill Andrews’ Testimonial: Partnering with bioaccess® for Breakthrough Telomere Therapy in Colombia

At the forefront of anti-aging innovation, Libella Gene Therapeutics is pioneering a groundbreaking approach to combat aging and declining health by leveraging the enzyme telomerase to lengthen telomeres. This ambitious mission brought Libella to Colombia, where the company has partnered with bioaccess® to establish clinical studies in collaboration with local hospitals and healthcare professionals.

Dr. William (Bill) Andrews, PhD, a renowned scientist in the field of anti-aging, shared his testimonial about his experience collaborating with bioaccess®. As the CEO of Sierra Sciences, a U.S.-based company focused on curing aging and declining health by lengthening telomeres, Dr. Andrews described how Libella licensed a gene therapy developed by Sierra Sciences to deliver telomerase to human cells. Libella initially struggled to navigate the complexities of launching clinical studies across different countries, including the United States. However, everything changed when Libella partnered with bioaccess®, formerly known as LATAM, to move their work forward in Colombia.

“My name is Bill Andrews. I run a company called Sierra Sciences in Reno, Nevada, in the United States that is totally focused on trying to find ways to cure aging and declining health by lengthening telomeres, using the enzyme telomerase,” Andrews explains. “We licensed a gene therapy that delivers telomerase to human cells in a Petri dish to a company called Libella Gene Therapeutics. And then they started working with bioaccess®, at the time they were called LATAM, to help get clinical studies underway in Colombia. Libella was struggling trying to find ways to connect with different countries, including the United States, to set up clinical studies, and that all turned around when Libella created an agreement with LATAM, now called bioaccess®.”

Dr. Andrews also highlighted the pivotal roles of Monica Mora, Julio Martinez, and Chris Venner in facilitating Libella’s success in Colombia. He praised Monica Mora’s exceptional organizational skills, Julio Martinez’s invaluable connections with Colombia’s top hospitals and leading medical professionals, and Chris Venner’s medical expertise in drafting technical protocols. Together, their efforts ensured that Libella’s clinical studies progressed smoothly and efficiently.

Reflecting on the collaboration, Dr. Andrews expressed his deep satisfaction with bioaccess®, describing the partnership as a game-changer for Libella’s mission to bring cutting-edge telomere therapy to patients in Colombia and beyond. He encourages other companies seeking to establish clinical studies in Colombia to consider bioaccess® as a trusted partner, citing their extensive network, professionalism, and commitment to excellence.

Interested in hearing more? Discover Dr. Andrews’ full story and learn how bioaccess® is driving innovation and healthcare progress in Latin America.